C. Roland Wolf
YOU?
Author Swipe
View article: Humanization of Drug Metabolism in the <i>Plasmodium berghei</i> Mouse Model for Antimalarial Drug Discovery
Humanization of Drug Metabolism in the <i>Plasmodium berghei</i> Mouse Model for Antimalarial Drug Discovery Open
Resistance to artemisinin-based combination therapies (ACTs) is steadily increasing in malaria-endemic countries, and new medicines to treat this disease are urgently needed. Drug discovery efforts are hindered by species differences in dr…
View article: Application of a mouse model humanized for cytochrome P450–mediated drug metabolism to predict drug-drug interactions between a peptide and small molecule drugs
Application of a mouse model humanized for cytochrome P450–mediated drug metabolism to predict drug-drug interactions between a peptide and small molecule drugs Open
Conventional preclinical in vitro approaches inaccurately predicted clinical trial outcomes of drug-drug interactions involving the peptide NN1177, a glucagon and glucagon-like peptide 1 receptor coagonist. To further study the mechanisms …
View article: A 10-Year Retrospective and Prospective Assessment of Trends in Electricity Supply and Demand and Associated Water Consumption in the Great Lakes St. Lawrence Region
A 10-Year Retrospective and Prospective Assessment of Trends in Electricity Supply and Demand and Associated Water Consumption in the Great Lakes St. Lawrence Region Open
The Conference of Great Lakes St. Lawrence Governors and Premiers (GSGP) is evaluating strategies to enhance the Region's economic competitiveness and appeal as a hub for future industries. It is assessing the availability and sustainabili…
View article: Novel <i>in vivo</i> TDP-43 stress reporter models to accelerate drug development in ALS
Novel <i>in vivo</i> TDP-43 stress reporter models to accelerate drug development in ALS Open
The development of therapies to combat neurodegenerative diseases is widely recognized as a research priority. Despite recent advances in understanding their molecular basis, there is a lack of suitable early biomarkers to test selected co…
View article: Acceleration of infectious disease drug discovery and development using a humanized model of drug metabolism
Acceleration of infectious disease drug discovery and development using a humanized model of drug metabolism Open
A key step in drug discovery, common to many disease areas, is preclinical demonstration of efficacy in a mouse model of disease. However, this demonstration and its translation to the clinic can be impeded by mouse-specific pathways of dr…
View article: Novel<i>in vivo</i>TDP-43 stress reporter models to accelerate drug development in ALS
Novel<i>in vivo</i>TDP-43 stress reporter models to accelerate drug development in ALS Open
The development of therapies to combat neurodegenerative diseases is widely recognised as a research priority, with conditions like Alzheimer’s, Amyotrophic lateral sclerosis (ALS) and Parkinson’s set to place an ever-heavier burden on hea…
View article: Simulating BRAFV600E-MEK-ERK signalling dynamics in response to vertical inhibition treatment strategies
Simulating BRAFV600E-MEK-ERK signalling dynamics in response to vertical inhibition treatment strategies Open
In vertical inhibition treatment strategies, multiple components of an intracellular pathway are simulta-neously inhibited. Vertical inhibition of the BRAFV600E-MEK-ERK signalling pathway is a standard of care for treating BRAFV600E-mutate…
View article: Potential of in vivo stress reporter models to reduce animal use and provide mechanistic insights in toxicity studies
Potential of in vivo stress reporter models to reduce animal use and provide mechanistic insights in toxicity studies Open
Chemical risk assessment ensures protection from the toxic effects of drugs and manmade chemicals. To comply with regulatory guidance, studies in complex organisms are required, as well as mechanistic studies to establish the relevance of …
View article: Supplementary Figures 6-7 from Olaparib, Monotherapy or with Ionizing Radiation, Exacerbates DNA Damage in Normal Tissues: Insights from a New p21 Reporter Mouse
Supplementary Figures 6-7 from Olaparib, Monotherapy or with Ionizing Radiation, Exacerbates DNA Damage in Normal Tissues: Insights from a New p21 Reporter Mouse Open
Figure S6: Beta-gal staining of uterus sections from untreated and irradiated p21 reporter mice. Figure S7: Beta-gal staining of whole lung, large intestine and liver sections from untreated and irradiated p21 reporter mice.
View article: Supplementary Figures 4-5 from Olaparib, Monotherapy or with Ionizing Radiation, Exacerbates DNA Damage in Normal Tissues: Insights from a New p21 Reporter Mouse
Supplementary Figures 4-5 from Olaparib, Monotherapy or with Ionizing Radiation, Exacerbates DNA Damage in Normal Tissues: Insights from a New p21 Reporter Mouse Open
Figure S4: Beta-gal staining of lung, liver, and kidney sections from untreated and irradiated p21 reporter mice. Figure S5: Beta-gal staining of spleen, thymus, and heart sections from untreated and irradiated p21 reporter mice.
View article: Supplementary Figures 11-13 from Olaparib, Monotherapy or with Ionizing Radiation, Exacerbates DNA Damage in Normal Tissues: Insights from a New p21 Reporter Mouse
Supplementary Figures 11-13 from Olaparib, Monotherapy or with Ionizing Radiation, Exacerbates DNA Damage in Normal Tissues: Insights from a New p21 Reporter Mouse Open
Figure S11: Bioluminescence from irradiated reporter mice. Figure S12: Visceral organ bioluminescence observed by invasive imaging. Figure S13: Pharmacokinetic parameters for olaparib in wild-type mice are linearly related to dose.
View article: Supplementary Figures 4-5 from Olaparib, Monotherapy or with Ionizing Radiation, Exacerbates DNA Damage in Normal Tissues: Insights from a New p21 Reporter Mouse
Supplementary Figures 4-5 from Olaparib, Monotherapy or with Ionizing Radiation, Exacerbates DNA Damage in Normal Tissues: Insights from a New p21 Reporter Mouse Open
Figure S4: Beta-gal staining of lung, liver, and kidney sections from untreated and irradiated p21 reporter mice. Figure S5: Beta-gal staining of spleen, thymus, and heart sections from untreated and irradiated p21 reporter mice.
View article: Supplementary Figure 10 from Olaparib, Monotherapy or with Ionizing Radiation, Exacerbates DNA Damage in Normal Tissues: Insights from a New p21 Reporter Mouse
Supplementary Figure 10 from Olaparib, Monotherapy or with Ionizing Radiation, Exacerbates DNA Damage in Normal Tissues: Insights from a New p21 Reporter Mouse Open
Figure S10: Beta-gal staining of various organs from control and etoposide-treated p21 reporter mice.
View article: Supplementary Figures 1-3 from Olaparib, Monotherapy or with Ionizing Radiation, Exacerbates DNA Damage in Normal Tissues: Insights from a New p21 Reporter Mouse
Supplementary Figures 1-3 from Olaparib, Monotherapy or with Ionizing Radiation, Exacerbates DNA Damage in Normal Tissues: Insights from a New p21 Reporter Mouse Open
Figure S1: Quantitative analysis of the immunoblots of Fig 1B. Figure S2: Quantitative analysis of the immunoblots of Fig 1C. Figure S3: Beta-gal staining of brain sections from an untreated p21 reporter mouse.
View article: Supplementary Figures 8-9 from Olaparib, Monotherapy or with Ionizing Radiation, Exacerbates DNA Damage in Normal Tissues: Insights from a New p21 Reporter Mouse
Supplementary Figures 8-9 from Olaparib, Monotherapy or with Ionizing Radiation, Exacerbates DNA Damage in Normal Tissues: Insights from a New p21 Reporter Mouse Open
Figure S8: Î’-gal staining is localized to the nucleus of cells. Figure S9: Kidney and liver function tests on plasma from cisplatin-treated reporter mice.
View article: Supplementary Figure 10 from Olaparib, Monotherapy or with Ionizing Radiation, Exacerbates DNA Damage in Normal Tissues: Insights from a New p21 Reporter Mouse
Supplementary Figure 10 from Olaparib, Monotherapy or with Ionizing Radiation, Exacerbates DNA Damage in Normal Tissues: Insights from a New p21 Reporter Mouse Open
Figure S10: Beta-gal staining of various organs from control and etoposide-treated p21 reporter mice.
View article: Supplementary Figures 8-9 from Olaparib, Monotherapy or with Ionizing Radiation, Exacerbates DNA Damage in Normal Tissues: Insights from a New p21 Reporter Mouse
Supplementary Figures 8-9 from Olaparib, Monotherapy or with Ionizing Radiation, Exacerbates DNA Damage in Normal Tissues: Insights from a New p21 Reporter Mouse Open
Figure S8: Î’-gal staining is localized to the nucleus of cells. Figure S9: Kidney and liver function tests on plasma from cisplatin-treated reporter mice.
View article: Data from Olaparib, Monotherapy or with Ionizing Radiation, Exacerbates DNA Damage in Normal Tissues: Insights from a New p21 Reporter Mouse
Data from Olaparib, Monotherapy or with Ionizing Radiation, Exacerbates DNA Damage in Normal Tissues: Insights from a New p21 Reporter Mouse Open
Many drugs targeting the DNA damage response are being developed as anticancer therapies, either as single agents or in combination with ionizing radiation (IR) or other cytotoxic agents. Numerous clinical trials in this area are either in…
View article: Supplementary Figures 6-7 from Olaparib, Monotherapy or with Ionizing Radiation, Exacerbates DNA Damage in Normal Tissues: Insights from a New p21 Reporter Mouse
Supplementary Figures 6-7 from Olaparib, Monotherapy or with Ionizing Radiation, Exacerbates DNA Damage in Normal Tissues: Insights from a New p21 Reporter Mouse Open
Figure S6: Beta-gal staining of uterus sections from untreated and irradiated p21 reporter mice. Figure S7: Beta-gal staining of whole lung, large intestine and liver sections from untreated and irradiated p21 reporter mice.
View article: SUPPORTING INFORMATION from Olaparib, Monotherapy or with Ionizing Radiation, Exacerbates DNA Damage in Normal Tissues: Insights from a New p21 Reporter Mouse
SUPPORTING INFORMATION from Olaparib, Monotherapy or with Ionizing Radiation, Exacerbates DNA Damage in Normal Tissues: Insights from a New p21 Reporter Mouse Open
Contains one Appendix, Supplementary Materials and Methods, Supplementary References, and Supplementary Figure Legends.
View article: Supplementary Figures 1-3 from Olaparib, Monotherapy or with Ionizing Radiation, Exacerbates DNA Damage in Normal Tissues: Insights from a New p21 Reporter Mouse
Supplementary Figures 1-3 from Olaparib, Monotherapy or with Ionizing Radiation, Exacerbates DNA Damage in Normal Tissues: Insights from a New p21 Reporter Mouse Open
Figure S1: Quantitative analysis of the immunoblots of Fig 1B. Figure S2: Quantitative analysis of the immunoblots of Fig 1C. Figure S3: Beta-gal staining of brain sections from an untreated p21 reporter mouse.
View article: Data from Olaparib, Monotherapy or with Ionizing Radiation, Exacerbates DNA Damage in Normal Tissues: Insights from a New p21 Reporter Mouse
Data from Olaparib, Monotherapy or with Ionizing Radiation, Exacerbates DNA Damage in Normal Tissues: Insights from a New p21 Reporter Mouse Open
Many drugs targeting the DNA damage response are being developed as anticancer therapies, either as single agents or in combination with ionizing radiation (IR) or other cytotoxic agents. Numerous clinical trials in this area are either in…
View article: Supplementary Figures 11-13 from Olaparib, Monotherapy or with Ionizing Radiation, Exacerbates DNA Damage in Normal Tissues: Insights from a New p21 Reporter Mouse
Supplementary Figures 11-13 from Olaparib, Monotherapy or with Ionizing Radiation, Exacerbates DNA Damage in Normal Tissues: Insights from a New p21 Reporter Mouse Open
Figure S11: Bioluminescence from irradiated reporter mice. Figure S12: Visceral organ bioluminescence observed by invasive imaging. Figure S13: Pharmacokinetic parameters for olaparib in wild-type mice are linearly related to dose.
View article: SUPPORTING INFORMATION from Olaparib, Monotherapy or with Ionizing Radiation, Exacerbates DNA Damage in Normal Tissues: Insights from a New p21 Reporter Mouse
SUPPORTING INFORMATION from Olaparib, Monotherapy or with Ionizing Radiation, Exacerbates DNA Damage in Normal Tissues: Insights from a New p21 Reporter Mouse Open
Contains one Appendix, Supplementary Materials and Methods, Supplementary References, and Supplementary Figure Legends.
View article: Data from Identification of Novel Pathways of Osimertinib Disposition and Potential Implications for the Outcome of Lung Cancer Therapy
Data from Identification of Novel Pathways of Osimertinib Disposition and Potential Implications for the Outcome of Lung Cancer Therapy Open
Purpose: Osimertinib is a third-generation inhibitor of the epidermal growth factor receptor used in treatment of non–small cell lung cancer. A full understanding of its disposition and capacity for interaction with other medications will …
View article: Data from Identification of Novel Pathways of Osimertinib Disposition and Potential Implications for the Outcome of Lung Cancer Therapy
Data from Identification of Novel Pathways of Osimertinib Disposition and Potential Implications for the Outcome of Lung Cancer Therapy Open
Purpose: Osimertinib is a third-generation inhibitor of the epidermal growth factor receptor used in treatment of non–small cell lung cancer. A full understanding of its disposition and capacity for interaction with other medications will …